FIELD: medicine; therapy.
SUBSTANCE: invention relates to the field of medicine, namely to therapy; it is intended for the treatment or prevention of a C5-related disease. A method for the treatment of prevention of a C5-related disease includes (a) intravenous administration to an individual of a single intravenous dose of an antibody to C5 at a dose of 500 mg, 1000 mg, or 1500 mg of the antibody, as well as (b) subcutaneous administration to an individual of two or more subcutaneous doses of the antibody to C5 (i) at a dose of 340 mg of the antibody once a week or every two weeks, or (ii) from 600 mg to 2000 mg of the antibody every four weeks. The specified antibody to C5 contains a sequence of a variable domain of a heavy chain (VH), consisting of an amino acid sequence SEQ ID NO: 2, a sequence of a variable domain of a light chain (VL), consisting of an amino acid sequence SEQ ID NO: 6, a sequence of a constant domain of a heavy chain (CH), consisting of an amino acid sequence SEQ ID NO: 13, and a sequence of a constant domain of a light chain (CL), consisting of an amino acid sequence SEQ ID NO: 18.
EFFECT: use of the invention allows for an increase in the efficiency and safety of treatment or prevention of C5-related disease.
11 cl, 10 dwg, 3 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION INTENDED FOR USE FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE AND METHOD FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE | 2019 |
|
RU2789389C2 |
DOSAGE AND REGIMEN FOR TREATING OR PREVENTING C5-RELATED DISEASES BY USING THE ANTI-C5 CROVALIMAB ANTIBODY | 2020 |
|
RU2823427C2 |
C5 ANTIBODIES AND METHODS FOR USING THEM | 2016 |
|
RU2742606C2 |
ANTI-C5 ANTIBODIES AND METHODS FOR THEIR USE | 2017 |
|
RU2789788C2 |
METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2662563C2 |
C5 ANTIBODY AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-RELATED DISEASES | 2014 |
|
RU2663349C2 |
POLYPEPTIDES BINDING TO HUMAN COMPLEMENT C5 | 2013 |
|
RU2654668C2 |
COMPLEMENT ACTIVITY MODULATORS | 2016 |
|
RU2733720C2 |
AGENT FOR DISEASE TREATMENT | 2009 |
|
RU2540018C2 |
COMPLEMENT ACTIVITY MODULATORS | 2016 |
|
RU2769701C2 |
Authors
Dates
2022-12-16—Published
2018-01-31—Filed